Session » Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 424

A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index

9:00AM-11:00AM: Abstract Number: 421

An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 428

Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 420

Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials

9:00AM-11:00AM: Abstract Number: 430

Axial Spondyloarthritis Patients Report Important Impairments in Daily Life and Work Ability – a Web Survey in 472 Patients

9:00AM-11:00AM: Abstract Number: 433

Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis

9:00AM-11:00AM: Abstract Number: 429

Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results

9:00AM-11:00AM: Abstract Number: 417

Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 427

Correlation Between Patient Reported Outcomes Measurement Information System (PROMIS) and RAPID3 in Rheumatoid Arthritis Patients Starting a New Biologic DMARD

9:00AM-11:00AM: Abstract Number: 444

Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration

9:00AM-11:00AM: Abstract Number: 425

Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN

9:00AM-11:00AM: Abstract Number: 440

Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome

9:00AM-11:00AM: Abstract Number: 432

Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 416

Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review

9:00AM-11:00AM: Abstract Number: 439

Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection

9:00AM-11:00AM: Abstract Number: 437

Is There Any Relationship Between Cardiovascular Comorbidity and a Patient-Acceptable Symptom State in Psoriatic Arthritis?

9:00AM-11:00AM: Abstract Number: 434

Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 438

Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?

9:00AM-11:00AM: Abstract Number: 442

Multidimensional Health Assessment Questionnaire (MDHAQ) as an Effective Screening Tool to Identify Concomitant Depression in Patients with Rheumatoid Arthritis and Spondyloarthritis in Routine Care

9:00AM-11:00AM: Abstract Number: 441

Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain

9:00AM-11:00AM: Abstract Number: 423

Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care – Was PRO Remission Achieved? Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 413

Performance of the Patient Reported Outcomes Measurement Information System 29-item Profile in Comparison to the Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) in an Australian Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 436

Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 431

Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 419

Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study

9:00AM-11:00AM: Abstract Number: 422

The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 426

Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo

9:00AM-11:00AM: Abstract Number: 414

Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 435

Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower

9:00AM-11:00AM: Abstract Number: 443

Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 415

Validation of a Satisfaction Measure for Use in Total Joint Replacement Clinical Trials

9:00AM-11:00AM: Abstract Number: 418

Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].